RENOSEM CO.,LTD
South Korea
Manufacturer/ Producer
RENOSEM CO., LTD. is an innovative provider of Low Temperature Plasma Sterilizer resulting in infection prevention, microbial reduction and RENOSEM strives to develop various medical devices using our own well-experienced high-tech plasma applications. RENOSEM CO., LTD. has been distributing state-of-the-art medical products through business partners globally. RENO Plasma Sterilizer protects patients and users from infection by means of surgical device 10-6 SAL (Sterility Assurance Level) e.g. most type of surgical endoscopes, catheters, cannula, etc. Low Temperature Plasma Sterilization is rapidly emerging as essential, which can sterilize humidity sensitive and heat sensitive medical device in OR, CSSD and General hospital, as well as Ophthalmology. Biolab, Veterinary clinic (Hospital), Dental clinic, and Pharmaceutical Aseptic industry. RENOSEM CO., LTD. focuses on the endeavor to come up to customers' needs and market situations.
Website
Manufacturer/ Producer
Unit 303-101, Techno Park III, 36-1, Samgeong-Dong, Ojeong-Gu, Bucheon-Shi,
421-742 Gyeonggi-Do - South Korea
Company info
Organisation
-
- Year established
- 2007
-
- pages.epage-home.site-status
- Registered office
-
- Main activity
- Manufacturer/ Producer
Activities of RENOSEM CO.,LTD
- Medical and surgical instruments
- Plasma Sterilizer
- Low Temperature Plasma Sterilizer
- low temperature sterilizer
- Hydrogen Peroxide Plasma Sterilizer
europages also recommends
A selection of companies related to the activity:
A selection of products that might interest you
MPS MICRO PRECISION SYSTEMS AG
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for quotes
Create one request and get multiple quotes form verified suppliers.
- Only relevant suppliers
- Data privacy compliant
- 100% free